NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains.